Introduction
The majority of hematopoietic stem and progenitor cells (HSPCs) reside in the bone marrow (BM) in a highly organized microenvironment, consisting of marrow stromal cells, osteoblasts, osteoclasts and other extracellular matrix proteins (for example, collagens, fibronectins, proteoglycans). [1] [2] [3] [4] [5] HSPCs express a number of cell surface molecules such as very late antigen 4 (VLA-4), CXCR4, CXCR2, CD44, CD62L, lymphocyte function-associated antigen-1, CD117 (c-kit) and Robo4 that mediate their adherence in the BM microenvironment. 3, 4, 6, 7 These interactions play important roles in regulating HSPC trafficking, as well as self-renewal, proliferation and differentiation processes. 4, 8 Mobilized HSPCs collected from peripheral blood have essentially replaced BM as a source of stem cells for autologous and allogeneic transplantation. There was initial concern with regard to the use of mobilized peripheral blood stem cells as a source of graft for allogeneic stem cell transplantation. This concern was based on the presence of a 10-to 50-fold increase in the T-cell content of the mobilized peripheral blood products, which could potentially lead to higher rates of acute and chronic graft-versus-host disease. However, transplantation with mobilized peripheral blood stem cells was associated with faster engraftment, reduced infectious complications, enhanced immune reconstitution, shorter hospitalization and reduced costs. [9] [10] [11] [12] Currently, granulocyte colony-stimulating factor (G-CSF) alone or G-CSF plus chemotherapy are the most commonly used methods for stem cell mobilization. Unfortunately, 5-30% of patients do not respond to these agents. 13 New strategies are needed to manage patients who fail initial mobilization, decrease the number of leukaphereses required to collect adequate number of HSPCs, improve immune reconstitution and decrease total cost. This article will first briefly review the standard approaches to HSPC mobilization using G-CSF. We will then discuss new strategies to mobilize stem cells through the use of CXCR4 and VLA-4 small-molecule antagonists.
Standard approaches to hematopoietic stem and progenitor cell mobilization
Cytokines, especially G-CSF, can be used alone or in combination with chemotherapy (disease-specific chemotherapy or cyclophosphamide) to increase the number of circulating CD34 þ cells, the surrogate marker of HSPCs in humans. [13] [14] [15] Studies have shown that although mobilization with G-CSF plus chemotherapy generates higher HSPC yield when compared with G-CSF alone, failure rates are not different between the two mobilization groups (5-30%). [16] [17] [18] Factors that may limit the collection of an adequate amount of CD34 þ HSPC include age, sex, extent and type of chemotherapy, previous use of immunomodulatory drugs, previous exposure to radiation, previous attempts at mobilization, depressed peripheral blood CD34 þ HSPC counts before mobilization, disease status and involvement of BM in the disease process. 19, 20 The optimal time for collection of stem cells after mobilization with chemotherapy plus G-CSF is 10-14 days as opposed to 4-5 days when G-CSF is used as single agent. 13 Although mobilization with chemotherapy plus G-CSF generally requires fewer leukaphereses to collect an adequate number of stem cells, individual differences in response to chemotherapy and the potential for complications result in more unpredictable collections that can delay the transplant and result in increased morbidity and cost. The use of chemotherapy as a part of mobilization is associated with significantly higher toxicities, including increased risk for secondary malignances, impairment of fertility, cardiac toxicity, hemorrhagic cystitis, anaphylactic reactions and higher cost.
G-CSF is well tolerated, with skeletal pain, fatigue and nausea being most frequent side effects. Rare episodes of spontaneous splenic rupture have been reported. [21] [22] [23] [24] Strategies to manage patients who fail their initial mobilization include dose escalation of G-CSF (12.5-50 mg/kg per day), addition of another cytokine such as GM-CSF, addition of chemotherapy or harvesting the BM; however, no standard approach exists. In general, patients who fail initial mobilization are more likely to fail remobilization regardless of the remobilization regimen. 17, 25 Furthermore, additional mobilization efforts often result in poorer patient outcomes and increased resource utilization. For these reasons, novel mobilization agents that are less toxic, more rapid and increase the yield of collected CD34 þ cells for transplantation are needed. Plerixafor (AMD3100, Mozobil; Genzyme, Cambridge, MA, USA), a novel small-molecule antagonist of CXCR4, was approved by the United States Food and Drug Administration (FDA) for use with G-CSF in December of 2008 to mobilize HSPC to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Below, we will briefly discuss CXCR4/CXCL12 biology and clinical results obtained using plerixafor as a mobilizing agent in autologous and allogeneic transplantation. We will then discuss some of the limitations with the use of plerixafor for HSPC mobilization and new agents in clinical development that target the CXCR4/CXCL12 axis.
HSPC mobilizing agents that target the CXCL12/CXCR4 axis CXCL12/CXCR4 axis CXCL12 or stromal cell-derived factor 1a (SDF-1a) is a chemokine that is constitutively produced at high levels in the BM by stromal cells such as osteoblasts, endothelial cells and a subset of reticular cells. [26] [27] [28] [29] [30] It is a potent chemoattractant for HSPCs and has been shown to regulate cell adhesion, survival and cell-cycle status. [31] [32] [33] CXCL12 requires the amino terminus of CXCR4 for binding and activates downstream signaling pathways via the second extracellular loop. 34 Further structurefunction studies indicate that the third intracellular loop of CXCR4 is necessary for G i -dependent signaling, and intracellular loops 2 and 3 as well as the C terminus part of CXCR4 are required for chemotaxis. 35 Interestingly, CXCL12 gene polymorphism has been proposed as a conditional factor for human CD34 þ stem cell mobilization, with the presence of the SDF1-3 0 A allele as a predictive factor of good CD34 þ cell mobilization. 36, 37 More recently, a second receptor, CXCR7, was identified that binds CXCL12 with an affinity that is approximately 10-fold higher than the affinity for CXCR4. 38, 39 Although the role of CXCR7 in CXCL12-dependent chemotaxis is not fully understood, there is evidence that CXCR7 lacks intrinsic chemotactic activity towards CXCL12 and rather functions by sequestering CXCL12 and modifying CXCR4 signaling. [40] [41] [42] [43] CXCR4 is a member of the large family of seven-transmembrane domain receptors coupled to heterotrimeric G i proteins and functions as a co-receptor for human immunodeficiency virus type 1 (HIV-1) cell entry. [44] [45] [46] [47] [48] CXCR4 exists in different isoforms as the result of differential splicing, which affect the length of its N terminus. 49 Post-translational modifications of CXCR4 include N-glycosylation, tyrosine sulfation and modification of tyrosine-21 by chondroitin sulfate. 49 The binding of CXCR4 to CXCL12 results in the activation of multiple signaltransduction pathways ultimately triggering chemotaxis. 49, 50 More recently, both trefoil factor family 2 (ref. 51) and macrophage migration-inhibiting factor 52 were described as additional ligands of CXCR4. Finally, the expression of CXCR4 on human CD34 þ stem cells is dynamic, and Flt3-ligand, 53 SCF, 54 IL-3, 55 IL-8, 56 hepatocyte growth factor 57 and G-CSF 58 are all known to modulate the SDF/CXCR4 pathway.
Genetic alteration of CXCR4
Mice deficient for CXCL12 or CXCR4 die perinatally and exhibit similar defects in neuron migration, organ vascularization and hematopoiesis. CXCR4
À/À and CXCL12 À/À embryos have severely reduced B-cell lymphopoiesis, reduced myelopoiesis in fetal liver and nearly complete loss of myelopoiesis in the BM. [59] [60] [61] [62] These data, along with the observation of increased numbers of circulating myeloid cells in the fetal blood of CXCR4-deficient embryos, 63 demonstrated the pivotal role for the CXCR4/CXCL12 axis in BM colonization.
As the lethality caused by deficiency in CXCR4 prevents analysis of its role in adult hematopoiesis, investigators generated hematopoietic chimeras by transferring CXCR4-deficient cells into lethally irradiated wild-type recipients. Unexpectedly, CXCR4
À/À fetal liver cells engrafted in the marrow of the irradiated recipients when high cell numbers were transplanted. [63] [64] [65] These results imply that early HSPC homing to the BM can occur in the absence of CXCR4. However, mice reconstituted with CXCR4-deficient fetal liver cells exhibited significantly reduced numbers of donor-derived B220 þ B cells, Mac-1 þ granulocytic-monocytic cells, Gr-1 þ granulocytic cells and CD61
þ megakaryocytic cells in the BM. [63] [64] [65] Furthermore, there was a marked increase in the number of circulating immature granulocytes, colony-forming unit-cells (CFU-Cs) (30-fold increase) and Lin À Sca-1 þ c-kit þ (LSK) cells in mice stably engrafted with CXCR4-deficient fetal liver cells. [63] [64] [65] In separate studies, CXCR4
À/À and wild-type BM cells were competitively transplanted into lethally irradiated congenic recipients, and HSPC engraftment was evaluated by their multi-lineage contribution to the peripheral blood at 8 weeks post-injection. 66 These experiments also revealed that CXCR4 À/À BM cells exhibited impaired engrafting capacity, with fivefold more CXCR4 À/À BM cells being required to achieve chimerism levels similar to the wild-type BM cells. Taken together, these data suggest that the impaired hematopoietic reconstitution potential of adoptively transferred CXCR4
À/À cells is related to their altered homing and retention within the BM microenvironment.
To further characterize the role of CXCR4 in hematopoietic stem cells, two groups have independently used the Cre-loxP recombination system to delete selectively CXCR4 in the hematopoietic system. In these studies, CXCR4-floxed mice were crossed with either MxCre- 33 or tamoxifen-inducible Cre 66 transgenic mice, and Cre was activated by injecting poly(I)-poly(C) or tamoxifen, respectively. Consistent with the phenotype of mice reconstituted with CXCR4-deficient fetal liver cells, conditional ablation of CXCR4 in mice caused a severe defect in B-cell lymphopoiesis and a significant increase in the number of circulating LSK stem cells. In both studies, primitive hematopoietic stem cells (LSK cells) were retained in the BM and became hyperproliferative following CXCR4 inactivation. 33, 66 In the study by Nie et al., 66 elevated numbers of BM and circulating LSK cell numbers as well as sustained hematopoiesis were observed for at least 8 months after tamoxifen induction of Cre and consequent excision of CXCR4. In contrast, Sugiyama et al. 33 reported a drastically reduced number of LSK cells in the BM and impaired hematopoiesis 4 months after poly(I)-poly(C)-mediated induction of Cre and deletion of CXCR4. Nie et al. 66 suggested that these discrepancies in the maintenance of LSK cells and hematopoiesis following CXCR4 ablation might be related to the toxicity of poly(I)-poly(C) on LSK cells. Whatever the explanation, the data indicate that HSPCs can be retained in the BM microenvironment through a CXCR4-independent mechanism. Furthermore, the hyperproliferative state of LSK cells following CXCR4 ablation indicates that CXCR4 acts intrinsically in primitive HSPCs to enforce quiescence. 66 
SPOTLIGHT
Additional evidence for the critical role that CXCR4 plays in leukocyte trafficking has been obtained from patients with the genetic immunodeficiency warts, hypogammaglobulinemia, infections, myelokathexis syndrome. Most cases of warts, hypogammaglobulinemia, infections, myelokathexis syndrome have been linked to autosomal dominant mutations in CXCR4, all of which truncate the C-terminal tail of CXCR4. [67] [68] [69] Multiple studies have demonstrated that loss of the intracellular tail of CXCR4 prevents its internalization and desensitization in response to CXCL12. 67, 68, 70 This loss of homologous desensitization leads to long-lasting activation of G proteins and sustained functional activity of the chemokine receptor as evidenced by increased chemotaxis to CXCL12, F-actin polymerization, intracellular calcium release and endothelial adhesion. 67, 68, 71 Some functional consequences of dysregulated CXCR4 signaling in warts, hypogammaglobulinemia, infections, myelokathexis syndrome is the failure of mature neutrophils to exit the BM (myelokathexis), resulting in peripheral neutropenia, defects in B-cell development, reduced immune function and other similarities to murine CXCL12-and CXCR4-deficient embryos. 72, 73 The data obtained from warts, hypogammaglobulinemia, infections, myelokathexis syndrome patients and studies using genetically modified mice support a model in which CXCL12 signaling through CXCR4 provides an important retention signal for HSPCs in the BM. Furthermore, multiple preclinical and clinical studies have shown that pharmacological disruption of the CXCL12/CXCR4 axis using various CXCR4 modulators, including small-molecule antagonists, peptide agonists and anti-CXCR4 antibodies, stimulate HSPC mobilization in a target-dependent manner. 74, 75 Below, we will discuss some of these different types of CXCR inhibitors in greater detail.
Plerixafor
Plerixafor is a bicyclam derivative that reversibly competes with and inhibits CXCL12 binding to CXCR4. This compound was originally tested clinically as an agent for the treatment of HIV infection by blocking the HIV entry into CD4 þ T cells. 76, 77 Initial studies in healthy volunteers showed good tolerance with minimal and reversible adverse effects. 78, 79 During those clinical trials, leukocytosis was noted after a single intravenous dose of plerixafor. Further investigation demonstrated that CD34 þ cells were one component of this generalized leukocytosis. Bioavailability after subcutaneous injection was 87%, with a dose-dependent increase in CD34 þ cells in the peripheral blood. No drug was detected after oral administration.
A single subcutaneous dose of plerixafor at 160-240 mg/kg resulted in a 6-to 10-fold increase in CD34 þ cell count starting 1 h, peaking at 9 h after injection and declining to baseline within 24 h. 80 Pharmacokinetic studies of plerixafor have identified no differences between older and younger patients. Thus, no dose adjustment beyond that based on renal function is recommended in elderly patients. The use of plerixafor has not been studied in individuals aged o18 years. Most frequently noted adverse effects were transient pain and injection site erythema, headache, paresthesias, diarrhea, bloating and nausea. An additional study showed that plerixafor could be combined with G-CSF to further increase the yield of CD34 þ cells. On the basis of these results, plerixafor was further pursued for HSPC mobilization in the clinical setting. 81 Testing of plerixafor as an HIV drug was abandoned owing to a lack of anti-viral effect and the occurrence of asymptomatic premature ventricular contractions in two patients.
Phase I studies with plerixafor Devine et al. 82 assessed safety and clinical effects of plerixafor in patients with NHL and MM. Plerixafor caused a rapid and statistically significant increase in the total white blood cells (WBCs) and peripheral blood CD34 þ cell counts at both 4 and 6 h following a single injection. The absolute number of circulating CD34 þ cells at 4 and 6 h after plerixafor administration was higher in the 240 mg/kg group compared with the 160 mg/kg group, with a maximum sixfold increase in circulating CD34 þ cells.
Phase II studies with plerixafor
The initial clinical trial of plerixafor in human HSPC mobilization by Flomenberg et al. 83 was based on the hypothesis that the combination of plerixafor plus G-CSF would be superior to G-CSF alone and that the plerixafor plus G-CSF-mobilized cells would engraft at least their G-CSF-mobilized counterparts. Patients with MM or NHL in first or second complete or partial remission were eligible for enrollment. Initially, patients were randomly assigned to receive plerixafor plus G-CSF or G-CSF alone as their mobilizing regimen, followed by a 2-week washout period and remobilization with the alternate regimen. Subsequently, randomization was discontinued and all patients received G-CSF alone as the initial mobilizing regimen. G-CSF mobilization consisted of the daily subcutaneous administration of the drug at a dose of 10 mg/kg and pheresis was begun on day 4 or 5 of administration. During plerixafor plus G-CSF mobilization, plerixafor was administered subcutaneously at a dose of 160-240 mg/kg beginning on day 4 or 5, followed 6 h later by apheresis. The apheresis procedure was limited to three blood volumes per day. Patients treated with plerixafor plus G-CSF mobilized more CD34 þ cells per leukapheresis, required fewer leukaphereses to reach the target CD34 þ cell count and mobilized higher total CD34 þ cell yield. In all, 56% of patients mobilized with plerixafor plus G-CSF yielded at least 2 Â 10 6
CD34
þ cells per kg recipient body weight after one leukapheresis and 100% after two leukaphereses (compared to 64% with G-CSF alone). In addition, all 9 of 25 patients who failed to yield the minimum CD34 þ cells per kg after four leukaphereses with G-CSF alone were successfully remobilized with plerixafor plus G-CSF.
Plerixafor given with G-CSF has been shown to mobilize CD34 þ cells in NHL, MM and Hodgkin's disease patients who could not collect sufficient cells for autologous transplant following other mobilization regimens. These poor mobilizers were excluded from company-sponsored trials, but have been included in a plerixafor Single Patient Use protocol, referred to as a Compassionate Use Protocol. A cohort of 115 data-audited poor mobilizers in Compassionate Use Protocol were assessed, with the objective being to collect 2 Â 10 6 CD34 þ cells per kg following plerixafor plus G-CSF mobilization. The rates of successful CD34 þ cell collection were similar for patients who previously failed chemotherapy mobilization or cytokine-only mobilization: NHLF60.3%, MMF71.4% and Hodgkin's diseaseF76.5%. Following transplant, median times to neutrophil and platelet engraftment were 11and 18 days, respectively. Engraftment was durable. 84 Several additional studies in heavily pretreated patients with NHL, Hodgkin's lymphoma and MM had similar results, confirming that plerixafor is a well-tolerated and effective mobilizing agent. [85] [86] [87] In addition, these studies support the use of plerixafor plus G-CSF in those patients who have failed initial attempts at mobilization with G-CSF or chemotherapy plus G-CSF. Pharmacokinetic and pharmacodynamic studies of plerixafor in patients with lymphoma and MM were comparable to those in healthy volunteers, supporting the current recommended dosing of plerixafor (240 mg/kg subcutaneous). 88 Plerixafor was also tested in combination with chemotherapy and G-CSF for HSPC mobilization in patients with MM and NHL. The addition of plerixafor to chemomobilization accelerated the rate of increase in CD34 þ cells. 89 However, the use of chemotherapy in plerixafor-based mobilization regimens is unlikely to be justified as adequate yield of HSPCs can be collected without subjecting the patient to the toxicities of chemotherapy. A retrospective study comparing plerixafor plus G-CSF to a historical cohort mobilized with chemotherapy plus G-CSF showed similar cost, but more predictable days of leukapheresis and less hospitalization in the plerixafor plus G-CSF group. 90 Phase III studies with plerixafor Two phase III, multicenter, randomized, double-blind, placebocontrolled studies compared plerixafor plus G-CSF to G-CSF alone for mobilization of stem cells in patients with MM and NHL. 91, 92 Patients received G-CSF at 10 mg/kg per day for 4 days, and on the evening of the fourth day, they received either plerixafor at 240 mg/kg subcutaneously or placebo. The leukaphereses were started on day 5, after the morning dose of G-CSF, and continued until CD34 þ cell yield was X5 Â 10 6 /kg (NHL) or X6 Â 10 6 /kg (MM) or a total of four leukaphereses. Patients continued receiving their morning dose of G-CSF and evening dose of study drug until collection was completed. Patients who failed to collect X2 Â 10 6 CD34 þ cells per kg with G-CSF alone were eligible for rescue with plerixafor plus G-CSF.
In the NHL trial (N ¼ 298), 59% of patients in the plerixafor arm reached the primary end point of 5 Â 10 6 CD34 þ cells per kg compared to 20% in the placebo arm (Po0.001). Importantly, 130/150 (87%) of patients in the plerixafor arm and only 70/148 (47%) in the placebo arm reached the secondary end point of at least 2 Â 10 6 CD34 þ cells per kg (Po0.001). Patients failing to yield at least 2 Â 10 6 CD34 þ cells per kg were eligible for 'rescue' mobilization with plerixafor plus G-CSF. After rescue therapy, 33/52 patients from the placebo arm and 4/10 patients from the plerixafor arm had successful remobilization. 93 A total of 35% of patients in the placebo arm failed the mobilization process vs 7% of patients in the plerixafor arm. In the MM trial (N ¼ 302), the primary end point of 6 Â 10 6 CD34 þ cells per kg was met in 72% of patients from the plerixafor group and only 34% from the placebo group (Po0.001).
In both the MM and NHL studies, plerixafor was well tolerated with minimal side effects. Patients receiving transplants had rapid hematopoietic recovery and durable grafts across all treatment groups. 91, 92 On the basis of the results of these two phase III, randomized, placebo-controlled trials, plerixafor was FDA approved, in combination with G-CSF, for HSPC mobilization in patients with NHL and MM in December 2008.
Use of plerixafor in allogeneic transplantation
Plerixafor was tested for HSPC mobilization in allogeneic transplantation. 94 Normal sibling donors were mobilized with plerixafor 240 mg/kg subcutaneously and underwent leukapheresis 4 h later. The FDA mandated for the first eight patients that we also collect, after a 10-day washout period, a G-CSF mobilized backup product. Two-thirds of the donors mobilized with plerixafor alone yielded the minimum goal of 2 Â 10 6 CD34 þ cells per kg recipient body weight after a single leukapheresis (100% after two collections; 20 l per apheresis). Allografts mobilized with plerixafor contained less CD34 þ cells and higher numbers of T, B and NK cells compared with G-CSFmobilized allografts (Table 1) . With a median follow-up of 277 days after allo-transplantation, engraftment was prompt, acute graft-versus-host disease (grades 2-4) occurred in 35% of patients and no unexpected adverse events were observed. It is possible that the allografts would have contained higher yields of CD34 þ cells if leukapheresis were started 6-10 h after plerixafor, which is considered the peak of mobilization in both patients and normal allogeneic donors. Several ongoing studies are testing different routes of administration (intravenous vs subcutaneous), doses and schedules of plerixafor alone or in combination with G-CSF for HSPC mobilization ( Table 2 ).
The pharmacokinetics of subcutaneous plerixafor requires that it be administered the night before leukapheresis, so that the morning collection would correspond to the peak of the circulating HSPCs. Such administration is associated with inconvenience and additional cost. To improve the kinetics of mobilization, intravenous plerixafor is being tested in both autologous and allogeneic HSPC transplant clinical trials (Table 1 ). In our phase I allogeneic transplant trial, 21 healthy donors were initially mobilized with increasing doses of intravenous plerixafor (80, 160, 240, 320 , 400 or 480 mg/kg).
95
After 4 days of drug clearance, the same donors were then mobilized with a single subcutaneous dose of 240 mg/kg plerixafor, followed 4 h later by leukapheresis. Peak numbers of circulating CD34 þ cells were observed 4-6 h after intravenous dosing (vs 6-9 h after subcutaneous dosing), and donors given 240 mg/kg intravenous plerixafor had higher peak levels of CD34 þ cells per ml compared with the same donors who received 240 mg/kg subcutaneous plerixafor. There was a clear dose-response relationship of intravenous plerixafor on mobilization of CD34 þ HSPCs, with the 320 mg/kg dose yielding a maximum eightfold increase in circulating CD34 þ cells at 4 h after injection. We also noted that intravenous dosing (especially doses 4240 mg/kg) resulted in prolonged mobilization of CD34 þ cells such that levels approached 20 CD34 þ cells per ml at 24 h after intravenous dosing. In our phase II study, 28 sibling donors were treated with plerixafor at a dose of 320 mg/kg by intravenous injection, followed 4 h later by leukapheresis. Successful mobilization was defined as a minimum leukapheresis yield of X2.0 Â 10 6 /kg CD34 þ cells per kg actual recipient body weight. Of 23 evaluable donors, six (26%) did not achieve the minimum cell dose of 2 Â 10 6 CD34 þ cells per kg in a single 20-l leukapheresis procedure. 96 This mobilization failure rate of 26% (6/23) with 320 mg/kg intravenous plerixafor is similar to the failure rate of 33% (15/45) we observe following administration of 240 mg/kg subcutaneous plerixafor. Four of the six patients who failed to collect X2.0 Â 10 6 CD34 þ cells per kg recipient body weight after their first leukapheresis procedure met the goal after a second mobilization and collection procedure. In both subcutaneous and intravenous plerixafor studies, only 3/68 normal allogeneic donors (4.4%) failed to mobilize 42 Â 10 6 CD34 þ cells per kg after two 20-l apheresis procedures.
Plerixafor and G-CSF mobilize phenotypically different CD34 þ cell subsets
Although evaluating the CD34 þ cells obtained from the eight healthy donors mobilized sequentially with plerixafor and G-CSF in our allogeneic transplant trial, we found that plerixafor SPOTLIGHT mobilized a population of CD34 dim cells, which were present on an average in nearly fivefold higher numbers compared with the G-CSF-mobilized CD34 þ cells. 97 Previous studies by others have demonstrated that human CD34 þ cells can be divided into at least three distinct subsets based on their cell surface expression of CD45RA and CD123 (IL-3Ra): 
Of interest, two of the important molecules responsible for stem cell homing, retention and trafficking, CXCR4 and VLA-4, were significantly overexpressed in the CD34 dim CD45RA þ subset compared with the CD34 þ CD45RA À and CD34 þ CD45RA þ cells. 100 A summary of the major differences between G-CSF-and plerixafor-mobilized stem cell grafts is shown in Table 1 . These differences were recently reviewed by Fruehauf and Tricot 101 and clearly indicate that the composition of G-CSF-and plerixafor-mobilized grafts are significantly different. What impact these different types of grafts have on the engraftment and function of HSPCs after hematopoietic stem cell transplantation remains largely unknown.
Alternative drugs in development targeting the CXCL12/CXCR4 axis
The success of plerixafor significantly addresses a number of the limitations involved with the use of G-CSF in hematopoietic stem cell mobilization. However, nearly one-third of healthy donors mobilized with plerixafor alone require more than one apheresis to obtain the minimal number of CD34 þ cells (X2.0 Â 10 6 CD34 þ cells per kg) necessary for transplantation. Furthermore, plerixafor was withdrawn from trials involving HIV patients owing to its lack of oral bioavailability and cardiotoxicity. Importantly, the cardiac-related side effect of plerixafor was not a result of the compound's ability to block CXCR4 function, but rather due to its presumed structural capacity for encapsulating metals. Because of these limitations, efforts to discover and develop potent and orally available inhibitors of the CXCR4/ CXCL12 axis continue. Below, we will discuss the status of some lead drug candidates that target the CXCR4/CXCL12 axis. Table 1 Comparison of HSPC mobilization by plerixafor and/or G-CSF POL6326 (Polyphor, Allschwil, Switzerland) is a selective and reversible CXCR4 inhibitor belonging to a novel drug class based on Polyphor's proprietary b-hairpin Protein Epitope Mimetics Technology. 102 The parent compound to POL6326, POL3026, was designed and optimized starting from the naturally occurring CXCR4 inhibitor polyphemusin-II. 103, 104 The design involved incorporating residues from a truncated polyphemusin-II analog (TC14011) into a macrocyclic templatebound b-hairpin mimetic. POL3026 binds at least 50-to 100-fold better to CXCR4 than does plerixafor. POL6326 was synthesized from POL3026 to improve its pharmacological properties while maintaining or improving potency and selectivity for CXCR4. A single injection of POL6326 to mice produces an 11-to 12-fold increase in circulating progenitor cells with a peak at 2-4 h post-dosing. 102 A phase I clinical trial involving administration of POL6326 to 74 healthy volunteers was successfully completed in the UK in July 2008. A phase IIa, proof-of-concept study to determine the degree of mobilization of CD34 þ cells following intravenous administration of POL6326 in patients with MM is ongoing (ClinicalTrials.gov Identifier NCT01105403). 105 BKT-140 (4F-benzoyl-TN14003; Biokine Therapeutics, Rehovot, Israel) is a 14-residue polypeptide antagonist of CXCR4 that was also downsized from polyphemusin-II. 106 BKT-140 binds CXCR4 with an affinity of approximately 1 nM and a single injection of the drug alone results in the mobilization of murine CFU-Cs (46-fold increase over baseline) that exhibit long-term hematopoietic reconstituting activity. 107, 108 Peripheral blood CFU-C levels peaked 2 h after BKT-140 administration and returned to baseline by 24 h. BKT-140 and G-CSF act synergistically to mobilize WBCs and HSPCs. Comparative studies between BKT-140 and plerixafor suggest that the two compounds bind and inhibit CXCR4 via different mechanisms.
SPOTLIGHT

108-110 BKT-140 functions as an inverse agonist and binds CXCR4 residues in extracellular domains and regions of the hydrophobic core proximal to the cell surface. In contrast, plerixafor functions as an antagonist 111 or weak partial agonist 109, 110 and binds amino acids in the central hydrophobic core of CXCR4. Interestingly BKT140, but not plerixafor, selectively, specifically and rapidly stimulates human leukemia and myeloma cell death in vitro and in vivo. NOX-A12 (NOXXON Pharma, Berlin, Germany) is an L-enantiomeric RNA oligonucleotide (Spiegelmer) that binds and neutralizes CXCL12. 114 Spiegelmers are mirror-image nuclease-resistant ribonucleotides that bind and inhibit target molecules in a manner conceptually similar to antibodies.
115,116
The 45-nucleotide-long NOX-A12 binds CXCL12 with an affinity of less than 1 nM and has a half-maximal inhibitory concentration value of 300 pM in a Jurkat cell migration assay. 114 Preclinical studies in the mouse and monkey indicate that NOX-A12 induces a dose-dependent mobilization of murine CFU-Cs and a 43-fold reversible mobilization of monkey WBCs with peak numbers of circulating cells being maintained between 3 and 8 h post-injection. A first-in-man clinical trial with NOX-A12 was successfully completed in May 2010 (ClinicalTrials.gov Identifier NCT00976378) and a multiple-dose phase I trial started in August 2010 (ClinicalTrials.gov Identifier NCT01194934). This second clinical study aims to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated intravenous doses of NOX-A12 alone and in combination with G-CSF in healthy subjects.
TG-0054 (Taigen Biotechnology, Taipei, Taiwan) is a CXCR4 antagonist of undisclosed structure. The compound blocks CXCL12 binding to CXCR4 with a half-maximal inhibitory concentration value of 10 nM. 117 In phase I study, the drug exhibited a favorable safety and pharmacokinetic profile in healthy subjects. 118 A single dose of TG-0054 at 1.12-4.40 mg/ kg resulted in a 3-to 14-fold increase in CD34 þ cell count starting at 2 h, peaking at 4-6 h after injection and declining to baseline within 24 h. The mean number of circulating CD34 þ cells averaged approximately 30 cells per ml at peak mobilization. 118 A phase II study to evaluate the safety, pharmacokinetics and hematopoietic stem cell mobilization of TG-0054 in patients with MM, non-Hodgkin's lymphoma or Hodgkin's disease is currently open (ClinicalTrials.gov Identifier NCT01018979).
MDX-1338 (BMS-936564; Medarex/Bristol-Myers Squibb, New York, NY, USA) is a fully human antibody that targets CXCR4. 119, 120 As MDX-1338 is an IgG 4 antibody, it lacks complement-dependent cytotoxicity activity and antibodydependent cell-mediated cytotoxicity activity. Preclinical studies have shown that MDX-1338 binds to CXCR4-expressing cells with low nanomolar affinity, blocks CXCL12 ligand binding to CXCR4-expressing cells and inhibits CXCL12-induced migration and calcium flux with low nanomolar half-maximal effective concentration (EC 50 ) values. 120 In addition, MDX-1338 also reduced tumor growth in acute myelogenous leukemia and lymphoma xenograft models. 119 A phase I, dose-escalation study of MDX-1338 as a monotherapy with chemotherapy is expected to enroll up to 34 patients with relapsed/refractory AML (ClinicalTrials.gov Identifier NCT01120457). Moreover, this trial is designed to establish and evaluate the safety, tolerability and maximum-tolerated dose, as well as preliminary pharmacodynamics and efficacy of MDX-1338. CXCR4 pepducins (Anchor Therapeutics, Cambridge, MA, USA) are highly stable synthetic lipopeptide pharmacophores that modulate CXCR4 activity from inside the cell membrane. 121 The CXCR4 receptor compounds are derived from the intracellular loops of CXCR4 and act as antagonists of CXCR4 G-protein signaling. 121 The pepducins PZ-218 and PZ-305 are based on the first intracellular loop of CXCR4, whereas PZ-210 targets the third intracellular loop. 122 Preclinical studies have shown that all three of these CXCR4 pepducins inhibit CXCL12-mediated calcium flux and chemotaxis of human neutrophils. 122 Furthermore, CXCR4 pepducins mobilized murine HSPCs that exhibit long-term hematopoietic reconstituting activity, with efficacy similar to plerixafor.
ALX-0651 (Ablynx, Zwijnaarde, Belgium) is an anti-CXCR4 Nanobody, which is being developed for hematopoietic stem cell mobilization. 123 Nanobodies are a novel class of therapeutic single-domain proteins derived from the smallest antibodybinding fragment of camelid heavy-chain-only antibodies. 124 Their discovery dates back to the early 1990s when HamersCasterman et al. 125 found that the sera of camels, dromedaries and llamas contain fully functional antibodies that lack light chains. These heavy-chain antibodies contain a single variable domain (VHH) and two constant domains (C H 2 and C H 3). The VHH domain is a perfectly stable polypeptide harboring the full antigen-binding capacity of the original heavy-chain antibody and forms the basis of the Nanobody technology. Ablynx reported the successful generation of two types of Nanobodies against CXCR4: highly potent antagonistic Nanobodies, as well as anti-CXCR4 Nanobodies with inverse agonist function. 123 Furthermore, they report that a single, intravenous administration of anti-CXCR4 Nanobody resulted in rapid mobilization of stem cells in a pre-clinical animal model. ALX-0651 is reportedly a biparatopic Nanobody directed against two different epitopes of CXCR4. AMD070 (Genzyme Corp., Cambridge, MA, USA) is an orally bioavailable non-cyclam CXCR4 antagonist derived from plerixafor. 126 Administration of AMD070 to HIV-1-infected patients suppressed the replication of X4 and dual/mixed strains of viruses. 127, 128 Leukocytosis followed AMD070 administration in all subjects, ranging from 1.3-fold (50-mg single dose subject) to 2.9-fold (400-mg single dose subject) above baseline, with a peak between 2 and 4 h after injection. 128 Similar kinetics and magnitudes of mobilization were observed across all leukocyte subsets tested, which included neutrophils, lymphocytes, monocytes, basophils, eosinophils, CD4 þ T cells and CD34 þ stem cells. AMD070 was slowly eliminated, with a terminal elimination half-life of 11-16 h. 128 Unfortunately, the FDA had to place AMD070 on clinical hold owing to liver histology changes in long-term preclinical toxicity studies.
GSK812397 (GlaxoSmithKline, Brentford, England) is a novel, orally bioavailable non-competitive CXCR4 antagonist. 129 The compound was developed from a structure-avidity study aimed at improving the anti-viral properties of AMD070 through iterative structural modifications. Preclinical studies have shown that GSK812397 binds to CXCR4-expressing cells with low nanomolar affinity, blocks infection of host cells by X4-utilizing SPOTLIGHT HIV-1 viruses and inhibits CXCL12-induced migration and calcium flux with low nanomolar EC 50 values. 129 The bioavailability of GSK812397 was similar across several species, including rat (21%), dog (21%) and monkey (17%). Furthermore, the half-life was greater than 12 h in both dog and monkey. No data have been published on the effects of GSK812397 on WBC and HSPC mobilization.
KRH-3955 (Kureha Chemical Industries, Nishiki, Japan) is an orally bioavailable, non-cyclam, non-peptide, small-molecule CXCR4 antagonist designed from KRH-1636. 130 KRH-1636 was discovered through screening more than 1000 compounds from the Kureha Corp chemical library. 131 Preclinical studies have shown that KRH-3955 binds to CXCR4-expressing cells with low nanomolar affinity, blocks infection of host cells by X4-utilizing HIV-1 viruses and inhibits CXCL12-induced calcium flux. 130 The compound shows an oral bioavailability of 26% in rats and an intravenous half-life of 99 h. The authors suggest that the long half-life of KRH-3955 is likely caused by its accumulation in tissues, which may be disadvantageous in terms of toxicity. 130 No data have been published on the effects of KRH-3955 on WBC and HSPC mobilization.
FC131 is a cyclopentapeptide (c(Gly 1 -D-Tyr 2 -Arg 3 -Arg 4 -Nal 5 ); Nal is 2-naphthylalanine) developed by molecular size reduction of the 14-residue T140 CXCR4 antagonist. 132 The size reduction (from T140 to FC131) was carried out based on the identification of the four bioactive amino-acid residues Arg2, Nal3, Tyr5 and Arg14 of the T140 molecule. Fuji et al. Studies to improve the pharmacokinetic profile of WZ811 led to the discovery of MSX-122 (WZ40). MSX-122 is an orally bioavailable small molecule that was produced by Metastatix Inc. (Tucker, GA, USA). There is a report that MSX-122 induces leukocytosis in monkeys beginning 4-6 h after administration with a peak total WBC count at 12-18 h that was 1.5-to 2-fold higher than baseline. 134 A phase I trial to determine the safety and pharmacokinetics of oral MSX-122 in patients with refractory metastatic or locally advanced solid tumors was suspended in June 2008 (ClinicalTrials.gov Identifier NCT00591682). No data have been published on the effects of WZ811 or MSX-122 on HSPC mobilization.
HSPC mobilizing agents that target VLA-4
Integrins
Integrins are a large family of transmembrane glycoproteins that mediate cell-cell and cell-matrix interaction and communication. [135] [136] [137] All integrins are non-covalently linked, heterodimeric molecules containing a a-and b-subunit. Each subunit contains a small cytoplasmic domain, a single transmembrane spanning region and a large extracellular domain. 138, 139 In vertebrates, 18 a-and 8 b-subunit genes have been identified and can combine to form 24 different integrin receptors, which vary in their ligand specificity, expression and signaling. 140 Integrin b1 (CD29) associates with at least 12 different a-subunits (a1-a11 and aV) and forms the largest integrin subfamily. The integrin chains a4, a5, a6 and a9 are expressed with b1 on HSPCs and play important roles in hematopoietic stem cell migration, homing and engraftment. 141, 142 Integrins mediate a wide variety of physiological processes, including adhesion, migration, survival and differentiation of cells. These functions are largely controlled by the strength of the ligand-binding affinity of the integrin. Integrin affinity for extracellular ligands is regulated through receptor clustering by multivalent ligands and/or conformational changes in the integrins. 143, 144 Extensive research has shown that integrins can adopt at least three major conformational states: (i) inactive (low affinity), (ii) primed or activated (high affinity) and (iii) ligand occupied. 144 Integrin activity is regulated through both the interactions of intracellular proteins with integrin cytoplasmic domains (inside-out activation) or by interactions with extracellular ligands (outside-in activation).
144-146
The a 4 integrin family 161, 162 found in the extracellular matrix. 163 VLA-4 also binds to osteopontin, mucosal addressin cell adhesion molecule 1, thrombospondin, intercellular adhesion molecule-4 and A disintegrin and a metalloprotease family members; however, the biological significance of these interactions is less clear. 140 The primary ligand for a 4 b 7 integrin is the immunoglobulin adhesion ligand mucosal addressin cell adhesion molecule 1. 164, 165 Both VCAM-1 and mucosal addressin cell adhesion molecule 1 are normally expressed in the gastrointestinal tract; however, VCAM expression extends into peripheral organs, 166, 167 whereas mucosal addressin cell adhesion molecule 1 expression is confined to organs of the gut. 166, 168, 169 VLA-4 is constitutively expressed on most leukocytes, including monocytes, lymphocytes, eosinophils, basophils and CD34 þ hematopoietic precursor cells. The expression of VLA-4 on CD34
þ HSPCs is known to be upregulated by IL-3 and SCF, 170 and downregulated by G-CSF. [170] [171] [172] [173] [174] [175] Studies by Lichterfeld et al. 175 showed that the affinity and avidity of VLA-4 for a soluble VCAM-1-Ig fusion protein was significantly reduced on circulating CD34
þ after treatment with G-CSF in comparison to CD34 þ cells from steady-state BM. Furthermore, the authors found that the number of circulating CD34 þ cells following G-CSF administration was inversely related to the number of CD34 þ /VCAM-1-Ig þ cells in the periphery, indicating that a low activation state of VLA-4 on CD34 þ cells during G-CSF mobilization is associated with a higher number of circulating HSPCs. 175 These observations suggest that both reduced VLA-4 expression and reduced VLA-4 avidity are associated with mobilization of CD34 þ cells by G-CSF.
Genetic ablation of VLA-4 in mice
Both the a 4 -and b1-subunits of VLA-4 have been inactivated in mice. Table 3 summarizes the phenotypes of mice following SPOTLIGHT genetic ablation of the a 4 or b1 integrin subunits, with a particular emphasis on the impact each deletion has on HSPC formation, maintenance, distribution and migration. As lack of a 4 or b 1 integrin is embryonic lethal owing to non-hematological defects, [176] [177] [178] somatic chimeric mice were generated by injecting a 4 or b 1 integrin-deficient embryonic stem cells into wild-type or recombination activating gene-deficient blastocysts. Although b 1 À/À HSPCs formed and were capable of differentiating into multiple cell lineages in vitro, they failed to migrate to the fetal liver (as well as adult sites of hematopoiesis) and establish hematopoiesis in the b 1 À/À /wildtype chimeras. [178] [179] [180] In contrast, a 4 integrins were not essential for HSPC colonization of the fetal liver in the somatic chimeric mice. 181, 182 These data suggest that a-subunits other than a 4 integrin mediate the migration of integrin b 1 þ HSPCs to sites of hematopoiesis during fetal development. However, a 4 integrin was absolutely required for hematopoietic maintenance and development, as the a 4 À/À /wild-type chimeras were incapable of completing erythroid, myeloid and lymphoid (B-and T-cell) differentiation in adult mice. 181, 182 The Cre/loxP system of conditional gene ablation, where one or more critical exons is flanked by loxP (floxed) sites to allow cell-specific knockout, has been used to examine the role of a 4 and b 1 integrins on adult BM-derived HSPCs. In contrast to the striking inability of a 4 or b 1 integrin-deficient HSPCs to be maintained and differentiate in somatic chimeric mice, conditional deletion of a 4 or b 1 integrin in adult mice caused much less severe perturbations in hematopoiesis. Genetic ablation of floxed a 4 integrin in both hematopoietic and non-hematopoietic compartments using Mx-Cre induced an eightfold increase in the number of circulating HSPCs (CFU-Cs) compared with a 4 þ / þ controls at 2 weeks after deletion. 183 Interestingly, the circulating levels of CFU-Cs remained significantly elevated for at least 50 weeks after a 4 integrin ablation and were accompanied by sequestration of CFU-Cs in the spleen. Similar long-term release of CFU-Cs into the peripheral blood was reported following deletion of floxed a 4 integrin in hematopoietic and endothelial cells using Tie2Cre. 184 To more clearly determine whether the alterations in progenitor biodistribution were solely caused by the loss of a 4 integrin on hematopoietic cells, BM cells from wild-type (a 4 þ / þ ) and a 4 -deficient animals were injected into lethally irradiated recipients and their homing, distribution and hematopoietic reconstitution potential were evaluated. Cells lacking a 4 integrins displayed impaired homing to the BM, increased numbers of circulating CFU-Cs and a competitive disadvantage in both short-and long-term hematopoietic reconstitution compared with normal competitors. [183] [184] [185] These data suggest that the expression of a 4 integrin on HSPCs plays an important role in their retention within the BM microenvironment. Of note, different results were obtained following transplantation of wild-type or a 4 -deficient cells isolated from the tissues of embryonic day 12.5 embryos into lethally irradiated adult recipients. 186 Here, a 4 integrin-deficient cells displayed similar hematopoietic engraftment, multi-lineage differentiation and competitive repopulation capacity compared to a 4 þ / þ cells. The reason for this discrepancy between the two transplant models remains unclear.
Somewhat conflicting results have also been reported following genetic ablation of b 1 integrin in adult BM-derived HSPCs. Initial experiments generated b 1 integrin-deficient HSPCs in vitro by transducing BM cells of mice homozygous for a floxed b 1 integrin gene with a Cre recombinase retrovirus. Transplantation of these ex vivo-generated b 1 À/À HSPCs into lethally irradiated recipients failed to provide radioprotection and BM engraftment. 179 In contrast, no significant alterations were reported in the number, distribution or function of b 1 Table 3 Phenotype of mice following genetic ablation of a 4 or b1 integrin subunits integrin-deficient HSPCs when they were generated in vivo using poly-IC and the MxCre/loxP system. 187 A similar lack of overt phenotype was reported when both b 1 and b 7 , which are the only known partners of a 4 integrin, were conditionally ablated in the hematopoietic system. 188 However, an eightfold increase in the number of circulating HSPCs was reported following genetic ablation of b 1 in both the hematopoietic and non-hematopoietic systems of b 7 -deficient mice. 188 This increase in circulating HSPCs is similar to the eightfold increase in circulating CFU-Cs observed following genetic ablation of a 4 , 183 and suggests that loss of b 1 integrin function on nonhematopoietic cells might contribute to the release of HSPCs from the BM to the peripheral blood.
SPOTLIGHT
Mobilization of HSPCs by anti-a 4 integrin antibodies
Studies with antibodies have also suggested that the VLA-4 receptor plays an important role during the migration of HSPCs to the BM and their retention in the BM. Treatment of donor BM cells with an a 4 integrin antibody before injection into lethally irradiated recipients inhibits their homing to the femurs of recipient mice. 189, 190 This inhibition of BM homing was accompanied by an increase in the number of HSPCs in the peripheral blood and spleen. As similar results were obtained by pretreatment of recipients with an antibody to VCAM-1, 189 a primary ligand for VLA-4, the data indicate that the VLA-4/ VCAM-1 axis plays an important role in the initial stages of HSPC homing to the BM.
Additional studies have shown that in vivo administration of antibodies to VLA-4 increases the number of circulating HSPCs in mice, primates and humans. The blockade of a 4 integrin in mice [189] [190] [191] [192] [193] [194] and non-human primates 191, 193, 195 results in rapid (o8 h) and prolonged (410 days) mobilization of HSPCs. Both CFU-C assays and transplantation experiments definitively demonstrated that the anti-a 4 integrin antibody mobilized committed progenitors and long-term repopulating cells. A functional kit receptor is required for HSPC mobilization by anti-a 4 integrin antibody, 194 and either additive or synergistic mobilization of HSPCs was observed when the antibody was combined with G-CSF, 193, 195 plerixafor, 191 kit ligand 193 and/or Flt3-ligand 193 . This enhanced mobilization of HSPCs following addition of G-CSF, plerixafor and/or Flt3-ligand to the anti-a 4 integrin antibody therapy is likely mediated via their disruption of CXCR4/CXCL12 signaling in the BM. 196 Finally, although no significant mobilization is observed following blockade of b 2 integrin alone, synergistic mobilization of murine and primate HSPCs occurs following concurrent inhibition of b 2 integrin and blockade of VLA-4 by administration of an anti-a 4 integrin antibody. 192 Elevated circulating levels of HSPCs are also observed following treatment of multiple sclerosis (MS) patients with an anti-VLA4 antibody. Natalizumab (Tysabri; Biogen/Idec, Cambridge, MA, USA) is a recombinant humanized neutralizing IgG4 monoclonal antibody that binds to the a 4 -subunit of the a 4 b 1 (VLA-4) and a 4 b 7 integrins. Natalizumab is approved by the FDA for the treatment of Crohn's disease and relapsing MS and is postulated to function in these conditions by inhibiting the transmigration of leukocytes through the blood-brain barrier (MS) and intestines (Crohn's). Similar to mice and non-human primates following anti-a 4 integrin antibody administration, natalizumab-treated MS patients display a rapid and sustained increase in circulating HSPCs. [197] [198] [199] Both CD34 þ cell counts and CFU-Cs were significantly increased within 24 h after a single injection of natalizumab to previously untreated MS patients. Overall, the number of circulating CD34 þ cells per ml blood increased three-to fivefold during the first 72 h after treatment and remained elevated at these levels (8-10 CD34 þ cells per ml) for at least a month after natalizumab injection. [197] [198] [199] Somewhat surprisingly, repeated administration of the antibody failed to mobilize additional CD34 þ cells. To put the magnitude of CD34 þ cell mobilization by natalizumab in context with other mobilizing regimens, the number of circulating CD34
þ cells in natalizumab-treated MS patients are approximately one-sixth and one-third of those observed in G-CSF-and plerixafor-treated healthy donors, respectively. 13, 94, [197] [198] [199] Finally, limited phenotyping studies on the CD34 þ cells mobilized by natalizumab indicated that they were primarily quiescent (490% in G 0 ), failed to transmigrate towards SDF-1 and belonged to the subset of more committed progenitors co-expressing CD38 and enriched for burst-forming unit-erythroid. [197] [198] [199] Although natalizumab has shown clinical efficacy and provided validation for the involvement of the a 4 integrin pathway in autoimmune and inflammatory conditions, its use as a clinical stem cell mobilizing agent in normal healthy donors is not justifiable because of its prolonged immune-modulating effects. More specifically, in addition to the prolonged mobilization of CD34 þ HSPCs, natalizumab also produces a lymphocytosis that can be sustained for at least a month after antibody administration. [200] [201] [202] [203] [204] This prolonged disruption of normal lymphocyte trafficking poses unacceptable risks to a healthy individual. Indeed, MS patients undergoing natalizumab monotherapy are at risk of developing progressive multifocal leukoencephalopathy. 205, 206 Progressive multifocal leukoencephalopathy is a rare and often fatal demyelinating disease of the central nervous system caused by infection of oligodendrocytes and astrocytes by the John Cunningham polyomavirus. As of May 2010, a total of 49 cases of progressive multifocal 
SPOTLIGHT
integrin antagonists
Because natalizumab has shown clinical efficacy in the treatment of MS and Crohn's disease, the development of small-molecule VLA-4 antagonists is seen as a promising pharmaceutical approach to a novel class of therapeutic agents. [207] [208] [209] [210] Small-molecule antagonist research in the a 4 integrin area has been ongoing for nearly 20 years and over 250 patents describing a 4 integrin antagonists as potential antiinflammatory agents have been published. 207 The smallmolecule antagonists of a 4 integrin that have progressed into clinical trials are summarized in Table 4 and can be classified into two major structures: (1) the tripeptide motif of leucineaspartic acid-valine mimics, whose sequence is responsible for VLA-4 interaction with fibronectin or (2) N-acylphenylalaninebased compounds. [208] [209] [210] In general, the leucine-aspartic acidvaline-based antagonists show high potency and selectivity for a 4 b 1 (VLA-4), whereas the N-acylphenylalanine derivatives exhibit dual inhibitory activity for both a 4 b 1 and a 4 b 7 . Early studies with the a 4 integrin antagonists suffered from poor bioavailability and a short half-life. More recent trials with orally active new-generation antagonists like SB-683699/firategrast, 208, 211 AJM-300 (refs 212,213) and Compound 14e 214 suggest that these compounds exhibit more favorable pharmacological properties. Finally, although many of the clinical trials listed in Table 4 have reported a transient lymphocytosis following antagonist administration, there is no published information on the effects these different a 4 integrin antagonists have on CD34
þ HSPC mobilization.
Mobilization of murine HSPCs by small-molecule antagonists of VLA-4
The mobilization of murine, primate and human HSPCs by a 4 integrin antibodies led to the hypothesis that small-molecule antagonists of a 4 integrins would represent a novel approach to mobilizing HSPCs.
is a potent (K d of o10 pM) and highly selective small-molecule inhibitor of both the unactivated and activated forms of human, mouse and rat a 4 b 1 integrin. 215 BIO5192 is an leucine-aspartic acid-valine-based a 4 integrin antagonist and exhibits high affinity for a 4 b 1 integrin because of an extremely slow dissociation rate (dissociation half-life 412 h) of the inhibitor from both the unactivated and activated states of a 4 b 1 integrin. The affinity of BIO5192 for a 4 b 1 integrin is at least 250-fold higher than for a 4 b 7 integrin. 215 Similar to the clinical trials involving a 4 integrin antagonists discussed above (Table 4) , initial preclinical studies using murine experimental models of autoimmune encephalomyelitis and other inflammatory diseases showed induction of leukocytosis and lymphocytosis following BIO5192 administration. 215 To determine whether HSPCs can be mobilized into the peripheral circulation by BIO5192, we treated mice with BIO5192 alone or in combination with plerixafor and/or G-CSF. We reported that blockade of a 4 b 1 integrin with a single injection of BIO5192 alone results in a 30-fold increase in mobilization of murine CFU-Cs over basal levels. 216 Peripheral blood CFU-GM levels peaked 0.5-1 h after BIO5192 administration and returned to baseline by 6 h. A similar magnitude of CFU-C mobilization was observed following treatment with plerixafor alone. Interestingly, an additive affect on HSPC mobilization was observed when BIO5192 was combined with plerixafor (threefold compared to plerixafor alone), G-CSF (fivefold compared to G-CSF alone) or their combination (17-fold compared to G-CSF alone). 216 Importantly, BIO5192 mobilized long-term repopulating cells that successfully engraft and expand in a multi-lineage manner in secondary transplant experiments. As BIO5192 will not be clinically developed, we have performed identical studies with similar results using the small-molecule VLA-4 antagonist firategrast, which is currently in clinical development for the treatment of MS by GlaxoSmithKline (data not shown). These data provided the first evidence for the utility of small-molecule inhibitors of VLA-4 either alone or in combination with G-CSF or plerixafor for mobilization of HSPCs.
To better understand the relationship between CXCR4 and VLA-4 in HSPC mobilization, Christopher et al.
196 generated CXCR4 À/À BM chimeras by transplanting CXCR4 À/À fetal liver cells into lethally irradiated wild-type recipient mice. Following hematopoietic reconstitution, the CXCR4 À/À chimeras were used to investigate the function of different mobilization agents in the absence of CXCR4/CXCL12 signaling. Surprisingly, mobilization by G-CSF or Grob was completely abrogated in CXCR4 À/À BM chimeras. 196 In contrast, HSPC mobilization by BIO5192 was robust, exhibiting a nearly 3000-fold increase in the number of circulating CFU-Cs in the CXCR4 À/À chimeras compared with untreated control mice. These observations suggest that a 4 integrin antagonist-induced mobilization of HSPCs occurs independently of CXCR4/CXCL12 signaling and further support the notion that CXCR4 and VLA-4 are the dominant receptors regulating HSPC migration from and retention within the BM.
Summary
Plerixafor represents a significant advance in stem cell mobilization. Mobilization with G-CSF plus plerixafor in autologous stem cell mobilization decreases the number of patients who fail to collect the minimum number of CD34 þ stem cells necessary for transplantation. 91, 92 Even in patients who are unlikely to fail mobilization with G-CSF alone, plerixafor provides the benefits of a higher stem cell yield and fewer apheresis procedures. Consequently, fewer patients will be transplanted with suboptimal numbers of HSPCs, which can lead to delayed hematopoietic recovery and the associated increases in blood transfusions, rates of infection and length of hospitalization.
Plerixafor is also effective as a single agent in the allogeneic transplant setting. We have demonstrated that hematopoietic stem cells mobilized by plerixafor alone are functional and provide prompt and durable hematopoietic engraftment following transplantation into HLA-identical siblings with advanced hematological malignancies. 94 These preliminary data demonstrate that the length of time required to mobilize and procure a functional hematopoietic allograft can be reduced from a 5-day to a 1-day process by directly targeting the CXCR4/CXCL12 axis. Unfortunately, nearly one-third of healthy donors mobilized with plerixafor alone fail to collect the minimal number of CD34 þ cells (X2.0 Â 10 6 CD34 þ cells per kg recipient body weight) necessary for transplantation in a single leukapheresis. One strategy being explored to reduce this mobilization failure rate is to design and develop a more potent CXCR4 inhibitor. Several novel CXCR4 inhibitors in various stages of clinical SPOTLIGHT development were discussed in this review. Alternatively, as an additive affect on murine HSPC mobilization is observed when plerixafor is combined with the VLA-4 antagonist BIO5192, 216 a more successful mobilization regimen might involve the co-administration of small-molecule inhibitors to CXCR4 and VLA-4. In general, the development of a G-CSF-free mobilization regimen is attractive both to avoid potential toxicities of G-CSF and to save time and resources during a 4-to 5-day G-CSF-based mobilization.
Recent research has shown that G-CSF induces HSPC mobilization by phagocyte depletion and modulation of the sympathetic nervous system (Figure 1) . [217] [218] [219] [220] [221] [222] [223] [224] Cxcl12 downregulation is critical in both of these processes, [217] [218] [219] [220] [221] [222] [223] [224] and no G-CSF-mediated mobilization is observed following neutralization of CXCR4 with monoclonal antibodies 225 or in CXCR4
À/À BM chimeras. 196 These data indicate that disruption of the CXCR4/CXCL12 axis plays a dominant role in HSPC mobilization by G-CSF. However, the observation that a single injection of plerixafor can synergize with multiple injections of G-CSF indicate that the mechanisms involved in G-CSF and plerixafor HSPC mobilization are not completely overlapping. 91, 92, 226 Combining the effects of G-CSF (phagocyte signaling and depletion, loss of osteoblasts, downregulation of HSPC retention genes like Cxcl12 in Nestin þ niche cells) with pharmacological inhibition of CXCR4 by plerixafor more effectively inhibits the CXCR4/CXCL12 axis and results in increased HSPC mobilization in vivo. Indeed, Chow et al. 217 recently showed that mimicking one effect of G-CSF administration, in vivo phagocyte depletion, before plerixafor treatment induced a twofold increase in the magnitude of HSPC mobilization by the drug.
Further, others and we have shown that plerixafor mobilizes HSPCs expressing higher levels of CXCR4 both before and during G-CSF administration. 7, 100, [227] [228] [229] Although not tested experimentally, it is tempting to speculate that these high CXCR4-expressing HSPCs are tethered to the BM microenvironment in a predominantly CXCR4-dependent manner and are less reliant on other adhesive interactions for their retention in the BM niche. Alternatively, G-CSF and plerixafor may mobilize HSPCs from different niches within the BM environment. In this regard, putative HSPCs have been found near the endosteum lined by osteoblasts (endosteal niche) and in association with sinusoidal endothelium (perivascular niche). 4, 8 Numerous reports have documented the importance of the VCAM-1/VLA-4 axis in modulating the homing and retention of HSPCs within the BM microenvironment. The observation that HSPCs are rapidly released into the peripheral circulation following targeted disruption of the VCAM-1/VLA-4 axis indicate that this interaction provides an alternative pathway for HSPC mobilization that is independent of the CXCR4/ CXCL12 axis. [189] [190] [191] [192] [193] [194] [196] [197] [198] [199] 216 This concept is further supported by the additive or synergistic mobilization of HSPCs that is observed following the addition of a VLA-4 inhibitor to a plerixafor-and/or G-CSF-based mobilization regimen. 191, 193, 216 Interestingly, although disruption of the CXCR4/CXCL12 axis via Cxcl12 downregulation appears to play a dominant role in HSPC mobilization by G-CSF, 196 it is important to note that the growth factor also downregulates the expression of transcripts encoding other HSPC retention genes, including SCF and VCAM-1, in cells that comprise the BM niche. 222 Downregulation of these alternative genes involved in HSPC retention within the BM microenvironment may be an additional mechanism whereby G-CSF induces greater mobilization of HSPCs relative to a specific inhibitor of CXCR4 like plerixafor. It is also important to note that the binding of CXCL12 to CXCR4 enhances the adhesive properties of HSCs by inside-out signaling, leading to the activation of the integrins VLA-4, VLA-5 and lymphocyte function-associated antigen-1. 153, [230] [231] [232] [233] As the CXCR4/CXCL12 and VCAM-1/VLA-4 axes interact in regulating HSPC trafficking and adhesion to the BM, others and we have sought to increase HSPC mobilization by co-administering inhibitors to both CXCR4 and VLA-4. 191, 216 This dual inhibitor approach may ultimately provide a more efficient method to collect a functional hematopoietic graft in a single day.
Following disruption of the adhesive interactions mediating stem cell retention in the BM niche, HSPCs must transit from the BM parenchyma through the endothelium and into the sinusoids, where they are temporarily retained until their release into the general circulation. Relatively little is known about the physiological mechanisms that govern the egress of HSPCs into the blood. Recent investigations have unveiled a role for the sphingosine-1-phosphate receptor 1 (S1P 1 ) in mobilizing HSPCs from the BM under steady-state conditions and following CXCR4 antagonist-mediated mobilization. [234] [235] [236] Receptors for S1P are present on human CD34
þ HSPCs and mediate their chemotactic response towards S1P as well as S1P-induced upregulation of integrins. [236] [237] [238] [239] [240] Although controversial, a shifted balance between intra-and extra-BM S1P might therefore play a role on HSPC mobilization into the peripheral blood. Interestingly, administration of an S1P 1 agonist, SEW2871, enhanced plerixafor-mediated mobilization. 235 These data imply that S1P receptors, particularly S1P 1 , regulate the egress of HSPCs from the BM.
Finally, CXCR4 and VLA-4 inhibitors are likely to find important uses beyond hematopoietic stem cell mobilization. CXCR4 inhibitors may function as therapeutic agents in cancer therapy as antimetastatic or chemosensitization agents, [241] [242] [243] [244] [245] as well as in inflammation and tissue repair. [246] [247] [248] [249] [250] [251] [252] [253] Furthermore, several studies have indicated an important role of VLA-4 in cell adhesion-mediated inflammatory pathologies, including asthma, MS, rheumatoid arthritis, atherosclerosis and inflammatory bowel disease. [208] [209] [210] Specific orally available small-molecule inhibitors of the VLA-4 interaction with its ligands would thus be expected to be of therapeutic benefit.
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